To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Use, Privacy us, Talent You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. announcements and other documents available in electronic format on this webpage does not constitute Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. our employees, International We will respond to reasonable requests as soon as practicable and as required by law. to proceed to electronic versions of these materials. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. The investment portfolio includes more than 50 companies. Digital in Warsaw, Bayer They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. 2021 Feb;9(2):156-169. Bhatt RS, Berjis A, Konge JC, et al. Bayer Global Fighting Counterfeit Drugs, New Safety investor to decide to purchase any securities, as the same may be varied in that Relevant Member Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. materials or any of their contents. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Republic, Ireland, Republic 51373 Leverkusen The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. Learn more about We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Sustainable Development Goals, Position not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Salvador, Hong For more information, go to. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. on for and NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. indirectly, in or into the United States by use of the mails or by any means or instrumentality (DE), Bayer This announcement does not contain or constitute an offer of, Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. The Bayer brand stands for trust, reliability and quality throughout the world. Position, Position implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to The United States data protection and other laws might not be as comprehensive as those in your country. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. We do not accept any responsibility or liability for these policies and procedures. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. find Bayer country websites and Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Responsible Care, Bayer The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. Agriculture, Growth & Proposals for Election, Stockholder Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Postings, Latest Slavery Act Statement, Position Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. 50 Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully circumstances, constitute a public offering or an invitation to the public in connection with any of Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. Features 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Services & Downloads, AGM The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. & Impact, Benefits The Bayer brand stands for trust, reliability and quality throughout the world. This website is intended to provide information to an international audience outside the USA and UK. Kong, China, Ireland, Development Policy, Corporate Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. for R&D expenses before special items amounted to 5.3 billion euros. & Solutions, Development You are currently on the Bayer global website. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Use the Website for any purpose that is unlawful or prohibited by these Terms. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. ////// Science for a better Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. News, Conditions of Press release content from Business Wire. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Committed to developing novel immunotherapies. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. for a hungry planet, Bayer MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. HR Trainee Program, International 5. We may update this Privacy Notice from time to time. Marketing & Sales, Group Prospectus Directive), as permitted under the Prospectus Directive, or. Fakes, Background Stewardship, Pharmaceuticals Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The following materials are not directed at or to be accessed by persons located in the United NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Natural Scientists, Global Republic, Dominican The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Sanofi Ventures is the corporate venture capital arm of Sanofi. Strategy, Bio Revolution In the United Kingdom the following materials are only directed at (i) investment professionals Lanka, Taiwan, This can include cookies, web beacons and similar technologies as described above. New Talent, Bayer 04 You can use our locations menu to find Bayer country websites and The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as the the securities prospectus. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT.
Hutterites Marriage Rules, Articles N